Home / News
|
17 June 2008 05:40 pm
West Malling, UK, 17 June 2008: Phoqus Pharmaceuticals plc (AIM: PQS) (“Phoqus” or the “Company”), the speciality pharmaceutical company, announces that the results of the Phase 2 clinical trial of Chronocort #004 were presented on 15 June by the NIH at the Endocrine Society meeting in San Francisco.
|
|
03 April 2008 10:04 am
A study by Crouch, et al. from the United Kingdom is the first study to evaluate genital sensitivity and sexual function in women with a history of congenital adrenal hyperplasia. The affects of feminizing genitoplasty on genital sensitivity have never been objectively evaluated until this study was performed.
|
|
Phoqus Pharmaceuticals Announces Positive Results from a Phase II study of its Novel Cortisol Replacement Therapy, Chronocort®
03 March 2008 01:09 pm
Primary and secondary endpoints successfully demonstrate clinical proof of concept in patients with Congenital Adrenal Hyperplasia. Company plans to proceed to a Phase III pivotal trial.
|
|
09 February 2008 09:37 am
A German woman who was mistakenly raised as a boy won a lawsuit against the surgeon who turned her into a man as a teenager, a court said on Thursday.
|
|
30 November 2007 02:05 pm
Bristol-Myers Squibb, manufacturers of the fludrocortisone tablet Florinef®, recently announced that due to production problems they will be changing the formula that will affect how the drug is stored. CAH Support Group Chairman, Sue Elford, contacted BMS to find out why.
|
|
28 November 2007 08:44 am
Phoqus Pharmaceuticals PLC said the open-label trial of Chronocort, its treatment for congenital adrenal hyperplasia, is progressing well and it expects to start late-stage clinical studies in the first half of 2008.
|
|
